The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
988
Trandolapril: An ACE Inhibitor for Treatment of Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Trandolapril: An ACE Inhibitor for Treatment of Hypertension
Trandolapril (tran doe la pril; Mavik - Knoll) has become the ninth angiotensin-converting- enzyme (ACE) inhibitor to be approved by the US Food and Drug Administration (FDA) for treatment of hypertension.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Trandolapril: An ACE Inhibitor for Treatment of Hypertension
Article code: 988b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.